Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad Laboratories (BIO) Q3 Earnings Miss Estimates
06:56pm, Wednesday, 29'th Oct 2025
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago.
Bio-Rad Reports Third-Quarter 2025 Financial Results
04:15pm, Wednesday, 29'th Oct 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
07:00am, Wednesday, 29'th Oct 2025
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
07:00am, Tuesday, 28'th Oct 2025
CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announce
Laxxon Medical to Attend BIO-Europe and Jefferies Healthcare Conference World Premier Life Science Partnering Events
07:00am, Monday, 27'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Laxxon announces attendance at BIO-Europe and Jefferies Healthcare Conference.
BKYI: BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland.
Securian Asset Management Inc. Sells 100 Shares of Bio-Rad Laboratories, Inc. $BIO
04:50am, Sunday, 26'th Oct 2025
Securian Asset Management Inc. trimmed its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 6.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,389 shar
Bio-Rad Laboratories, Inc. $BIO Shares Sold by DekaBank Deutsche Girozentrale
04:12am, Sunday, 26'th Oct 2025
DekaBank Deutsche Girozentrale lessened its stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 12
Compelling Value In Small-Cap Equities And Select Cyclicals
11:45pm, Thursday, 23'rd Oct 2025
Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B)
7 Stocks Taking The Next Step To Be On Offense
07:30pm, Thursday, 23'rd Oct 2025
Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Wednesday, 22'nd Oct 2025
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Laboratories (BIO) to Release Earnings on Wednesday
03:50am, Wednesday, 22'nd Oct 2025
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) is expected to announce its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $
BIO-key Introduces EcoID III USB Fingerprint Scanner Delivering FBI FAP 20 Certification, Liveness Detection and Encrypted Device-to-Host Communication.
Analysts Set Bio-Rad Laboratories, Inc. (NYSE:BIO) PT at $333.50
01:14am, Monday, 20'th Oct 2025
Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One investment anal
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
05:30pm, Thursday, 16'th Oct 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
